Metabolic alterations in renal cell carcinoma.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Treatment Reviews

• Publication date

  2015-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ctrv.2015.07.002PMID 26169313
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells

  2015cited by this paper
• Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib

  2015cited by this paper
• Emerging tyrosine kinase inhibitors for the treatment of renal cancer

  2015cited by this paper
• Fructose-1, 6-bisphosphatase opposes renal carcinoma progression

  2014cited by this paper
• Succinate Dehydrogenase (SDH)-deficient Renal Carcinoma: A Morphologically Distinct Entity

  2014cited by this paper
• Tuberous Sclerosis–associated Renal Cell Carcinoma: A Clinicopathologic Study of 57 Separate Carcinomas in 18 Patients

  2014cited by this paper
• The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.

  2014cited by this paper
• Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.

  2013cited by this paper
• Suppression of Gluconeogenic Gene Expression by LSD1-Mediated Histone Demethylation

  2013cited by this paper
• Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

  2013cited by this paper
• Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer.

  2013cited by this paper
• Where are we going with ulcerative colitis management?

  2013cited by this paper
• Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner

  2013cited by this paper
• Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft.

  2013cited by this paper
• COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA

  2013cited by this paper
• Molecular Pathways: Fumarate Hydratase-Deficient Kidney Cancer—Targeting the Warburg Effect in Cancer

  2013cited by this paper
• The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia

  2013cited by this paper
• Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality.

  2013cited by this paper
• Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.

  2012cited by this paper
• Englerin A Selectively Induces Necrosis in Human Renal Cancer Cells

  2012cited by this paper
• mTOR signaling in growth control and disease.

  2012cited by this paper
• Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma

  2012cited by this paper
• Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

  2012cited by this paper
• Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia

  2012cited by this paper
• A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer.

  2012cited by this paper
• BAP1 loss defines a new class of renal cell carcinoma

  2012cited by this paper
• Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice.

  2012cited by this paper
• Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors

  2011cited by this paper
• Renal Tumors Associated With Germline SDHB Mutation Show Distinctive Morphology

  2011cited by this paper
• Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 Signaling

  2011cited by this paper
• mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway.

  2011cited by this paper
• Promoter Hypermethylation Mediated Downregulation of FBP1 in Human Hepatocellular Carcinoma and Colon Cancer

  2011cited by this paper
• An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.

  2011cited by this paper
• Reductive carboxylation supports growth in tumor cells with defective mitochondria

  2011cited by this paper
• The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.

  2011cited by this paper
• An overview of the c-MET signaling pathway

  2011cited by this paper
• Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?

  2010cited by this paper
• UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.

  2010cited by this paper
• AMPK as a therapeutic target in renal cell carcinoma

  2010cited by this paper
• mTORC1 controls fasting-induced ketogenesis and its modulation by ageing

  2010cited by this paper
• Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

  2010cited by this paper
• The genetic basis of kidney cancer: a metabolic disease

  2010cited by this paper
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  2010cited by this paper
• Activation of a metabolic gene regulatory network downstream of mTOR complex 1.

  2010cited by this paper
• Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma

  2010cited by this paper
• Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis

  2010cited by this paper
• Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2

  2009cited by this paper
• Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

  2009cited by this paper
• LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer

  2009cited by this paper
• Tumor suppressors and cell metabolism: a recipe for cancer growth.

  2009cited by this paper
• Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1α Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species

  2009cited by this paper
• Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization

  2009cited by this paper
• Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

  2009cited by this paper
• SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth

  2008cited by this paper
• Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.

  2008cited by this paper
• HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.

  2008cited by this paper
• Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients

  2008cited by this paper
• ROS-Generating Mitochondrial DNA Mutations Can Regulate Tumor Cell Metastasis

  2008cited by this paper
• Identification and characterization of a novel folliculin-interacting protein FNIP2.

  2008cited by this paper
• Disruption of Tsc2 in pancreatic β cells induces β cell mass expansion and improved glucose tolerance in a TORC1-dependent manner

  2008cited by this paper
• A sweet new role for EGFR in cancer.

  2008cited by this paper
• Metastasis is promoted by a bioenergetic switch: New targets for progressive renal cell cancer

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy.

  2008cited by this paper
• The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes.

  2007cited by this paper
• Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis

  2007cited by this paper
• HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity.

  2007cited by this paper
• AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer.

  2007cited by this paper
• Activation of the mTOR signaling pathway in renal clear cell carcinoma.

  2007cited by this paper
• Hypoxia-inducible Factor 1α Is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR Signaling Motif*

  2007cited by this paper
• The Morphologic Spectrum of Kidney Tumors in Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Syndrome

  2007cited by this paper
• Inhibitory effect of tumor cell-derived lactic acid on human T cells.

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer.

  2007cited by this paper
• Acid-mediated tumor invasion: a multidisciplinary study.

  2006cited by this paper
• Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation.

  2006cited by this paper
• TOR signaling in growth and metabolism.

  2006cited by this paper
• The tuberous sclerosis complex.

  2006cited by this paper
• Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling

  2006cited by this paper
• HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption.

  2006cited by this paper
• Molecular pathways in renal cell carcinoma--rationale for targeted treatment.

  2006cited by this paper
• Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer

  2006cited by this paper
• Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase.

  2005cited by this paper
• Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells.

  2005cited by this paper
• ATP citrate lyase inhibition can suppress tumor cell growth.

  2005cited by this paper
• Differential Gene Up-Regulation by Hypoxia-Inducible Factor-1α and Hypoxia-Inducible Factor-2α in HEK293T Cells

  2005cited by this paper
• HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability.

  2005cited by this paper
• regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis.

  2004cited by this paper
• Phase II trial of topotecan in patients with advanced renal cell carcinoma

  2004cited by this paper
• Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

  2004cited by this paper
• Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1

  2004cited by this paper
• Upstream and downstream of mTOR.

  2004cited by this paper
• Phase II trial of bortezomib for patients with advanced renal cell carcinoma.

  2004cited by this paper
• Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.

  2004cited by this paper
• Rheb promotes cell growth as a component of the insulin/TOR signalling network

  2003cited by this paper
• Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.

  2003cited by this paper
• TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

  2003cited by this paper

• Reprogramming the tumor microenvironment: methylmalonic acid at the intersection of ccRCC metabolism and macrophage polarization.

  2026cites this paper
• Kynurenine Metabolism Mediates Tumor Progression in Renal Cell Carcinoma

  2026cites this paper
• Centrosome dysfunction and autophagy dysregulation in renal cell carcinoma: Implications for tumor progression and therapy.

  2025cites this paper
• Regulatory T cells in renal cell carcinoma: tumor-promoting mechanisms and emerging therapeutic strategies.

  2025cites this paper
• PIK‐III‐Mediated Elevation of Thiamine Re‐Sensitises Renal Cell Carcinoma to Cuproptosis via Activating PDHA1

  2025cites this paper
• Identification and validation of prognostic models and tumor microenvironment infiltration characteristics for tRNA modification regulators in clear cell renal cell carcinoma

  2025cites this paper
• Oncocytic Tumors in the Kidney: A Tri-Focal Review – Integrated Pathological, Cytopathological, and Molecular Perspectives, Part 2

  2025cites this paper
• Protein succinylation mechanisms and potential targeted therapies in urinary disease.

  2025cites this paper
• Metabolic Supremacy Fuels Tumor Aggressiveness in Renal Cancer

  2025cites this paper
• Exploring Metabolic Shifts in Kidney Cancer and Non-Cancer Cells Under Pro- and Anti-Apoptotic Treatments Using NMR Metabolomics

  2025cites this paper
• A phase II study of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma patients: NivoMet TWINS-GU002 Study

  2025cites this paper
• Resveratrol liposomes reverse sorafenib resistance in renal cell carcinoma models by modulating PI3K-AKT-mTOR and VHL-HIF signaling pathways

  2024cites this paper
• Chromatin Helicase CHD6 Establishes Pro-inflammatory Enhancers and is a Synthetic Lethal Target in FH-Deficient Renal Cell Carcinoma.

  2024cites this paper
• Identification of clear cell renal cell carcinoma subtypes by integrating radiomics and transcriptomics

  2024cites this paper
• MiR-150-5p contributes to unexplained recurrent spontaneous abortion by targeting VEGFA and downregulating the PI3K/AKT/mTOR signaling pathway

  2023cites this paper
• hsa_circ_0003596, as a novel oncogene, regulates the malignant behavior of renal cell carcinoma by modulating glycolysis

  2023cites this paper
• The Role of AMPK Subunits in Clear Cell Re-nal Cell Carcinoma Based on Biological In-formation Analysis

  2023cites this paper
• Liver‐Inspired Polyetherketoneketone Scaffolds Simulate Regenerative Signals and Mobilize Anti‐Inflammatory Reserves to Reprogram Macrophage Metabolism for Boosted Osteoporotic Osseointegration

  2023cites this paper
• MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria‐dependent dephosphorylation of EGFR

  2023cites this paper
• Metabolic reprogramming of clear cell renal cell carcinoma

  2023cites this paper
• PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis

  2023cites this paper
• The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma

  2023cites this paper
• Redox Metabolism-Associated Molecular Classification of Clear Cell Renal Cell Carcinoma

  2022influential citation
• SPTBN1 abrogates renal clear cell carcinoma progression via glycolysis reprogramming in a GPT2-dependent manner

  2022cites this paper
• Multiparametric Magnetic Resonance Imaging and Metabolic Characterization of Patient-Derived Xenograft Models of Clear Cell Renal Cell Carcinoma

  2022cites this paper
• The cross‐talk between Abl2 tyrosine kinase and TGFβ1 signalling modulates the invasion of clear cell Renal Cell Carcinoma cells

  2022cites this paper
• Metabolic signatures of immune cells in chronic kidney disease

  2022cites this paper
• Abnormal expression of HADH, an enzyme of fatty acid oxidation, affects tumor development and prognosis

  2022cites this paper
• Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma

  2022cites this paper
• Identification of subtypes of clear cell renal cell carcinoma and construction of a prognostic model based on fatty acid metabolism genes

  2022cites this paper
• Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study.

  2022cites this paper
• Functional Characterization of FH Mutation c.557G>A Underlies Uterine Leiomyomas

  2022cites this paper
• Identification of a Novel Glycolysis-Related Gene Signature Correlates With the Prognosis and Therapeutic Responses in Patients With Clear Cell Renal Cell Carcinoma

  2021cites this paper
• Does the Urinary Proteome Reflect ccRCC Stage and Grade Progression?

  2021cites this paper
• Monocarboxylate transporter 1 promotes proliferation and invasion of renal cancer cells by mediating acetate transport

  2021cites this paper
• Response to: Correspondence on ‘Role of AMPK/mTOR-independent autophagy in clear cell renal cell carcinoma’ by Lorzadeh et al

  2021cites this paper
• The Hypoxic Microenvironment Induces Stearoyl-CoA Desaturase-1 Overexpression and Lipidomic Profile Changes in Clear Cell Renal Cell Carcinoma

  2021cites this paper
• The Heterogeneity Metabolism of Renal Cell Carcinomas.

  2021cites this paper
• SDHB Suppresses the Tumorigenesis and Development of ccRCC by Inhibiting Glycolysis

  2021cites this paper
• Diagnostic and prognostic value of ABC transporter family member ABCG1 gene in clear cell renal cell carcinoma

  2021cites this paper
• Functional Assessment of Four Novel Immune-Related Biomarkers in the Pathogenesis of Clear Cell Renal Cell Carcinoma

  2021cites this paper
• Expression and prognostic significance of fatty acid synthase in clear cell renal cell carcinoma.

  2020cites this paper
• Renal Cell Carcinoma: genomic landscape and clinical implications

  2020cites this paper
• Nucleobindin-2 enhances the epithelial-mesenchymal transition in renal cell carcinoma

  2020cites this paper
• Metformin: the updated protective property in kidney disease

  2020cites this paper
• Role of AMPK/mTOR-independent autophagy in clear cell renal cell carcinoma

  2020cites this paper
• Exploring the Spectrum of Kidney Ciliopathies

  2020cites this paper
• Cell Adhesion-Related Molecules Play a Key Role in Renal Cancer Progression by Multinetwork Analysis

  2019cites this paper
• Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges

  2019cites this paper
• The mRNA Expression Signature and Prognostic Analysis of Multiple Fatty Acid Metabolic Enzymes in Clear Cell Renal Cell Carcinoma

  2019influential citation
• Prognostic Implication of pAMPK Immunohistochemical Staining by Subcellular Location and Its Association with SMAD Protein Expression in Clear Cell Renal Cell Carcinoma

  2019influential citation
• Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK

  2019cites this paper
• MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma

  2019cites this paper
• Uptake in Clear Cell Renal Cell Carcinoma

  2019cites this paper
• Toward a genome-based treatment landscape for renal cell carcinoma.

  2019cites this paper
• Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?

  2019cites this paper
• Inactivation of the AMPK-GATA3-ECHS1 Pathway induces Fatty Acid Synthesis that Promotes Clear Cell Renal Cell Carcinoma Growth.

  2019cites this paper
• Fructose 1,6-Bisphosphatase 1 Expression Reduces 18F-FDG Uptake in Clear Cell Renal Cell Carcinoma

  2019cites this paper
• Comprehensive analysis of differentially expressed profiles and reconstruction of a competing endogenous RNA network in papillary renal cell carcinoma

  2019cites this paper
• Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma

  2018cites this paper
• Overexpression of ATP citrate lyase in renal cell carcinoma tissues and its effect on the human renal carcinoma cells in vitro

  2018cites this paper
• PARP10 (ARTD10) modulates mitochondrial function

  2018cites this paper
• CLONAL EVOLUTION AND HETEROGENEITY OF CANCER IN THE CONTEXT OF INDIVIDUALIZED MEDICINE

  2018cites this paper
• FUNCTIONAL TESTING OF UROLOGICAL CANCER MODELS BY RNAi AND DRUG LIBRARIES

  2018cites this paper
• miR-150-5p suppresses tumor progression by targeting VEGFA in colorectal cancer

  2018cites this paper
• SP1-induced lncRNA-ZFAS1 contributes to colorectal cancer progression via the miR-150-5p/VEGFA axis

  2018cites this paper
• Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells

  2018cites this paper
• A novel function of NUCB2 in promoting the development and invasion of renal cell carcinoma.

  2017influential citation
• Data‐Independent Acquisition‐Based Quantitative Proteomic Analysis Reveals Potential Biomarkers of Kidney Cancer

  2017cites this paper
• Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear‐Cell Renal‐Cell Carcinoma

  2017cites this paper
• Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma

  2017cites this paper
• Reduced E-cadherin facilitates renal cell carcinoma progression by WNT/β-catenin signaling activation

  2017cites this paper
• 18F-fluorodeoxyglucose uptake predicts MET expression in lung adenocarcinoma

  2017cites this paper
• Imaging and Screening of Hereditary Cancer Syndromes.

  2017cites this paper
• Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma.

  2017cites this paper
• Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma

  2017cites this paper
• Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?

  2016cites this paper
• Molecular Genetics of Renal Cancer

  2016cites this paper
• The role of precision medicine for the treatment of metastatic renal cell carcinoma

  2016cites this paper
• Genetic Alteration in Phosphofructokinase Family Promotes Growth of Muscle-Invasive Bladder Cancer

  2016cites this paper
• The prospect of precision therapy for renal cell carcinoma.

  2016cites this paper
• Inhibition of pentose phosphate pathway suppresses acute myelogenous leukemia

  2016cites this paper
• A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor‐targeted therapies

  2016cites this paper
• c-Myc modulates glucose metabolism via regulation of miR-184/PKM2 pathway in clear-cell renal cell carcinoma.

  2016cites this paper
• The Microphthalmia-Associated Transcription Factor p.E318K Mutation Does Not Play a Major Role in Sporadic Renal Cell Tumors from Caucasian Patients

  2016cites this paper
• FLIPL is critical for aerobic glycolysis in hepatocellular carcinoma

  2016cites this paper
• Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma

  2016cites this paper